Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
Date:2/5/2009

ongoing discussions with regulatory authorities and the potential goals, progress, timing and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential inability to reach final agreement with regulatory agencies on the use of a surrogate endpoint and phase 3 trial design for Amigal; the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier clinical trials may not be predictive of future results. Additionally, with respect to statements regarding projections of the Company's cash position and expected use of cash during 2009, actual results may differ based on market factors, the company's ability to execute its operational and budget plans, and its achievement of milestones and receipt of milestone payments from Shire. Additionally, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2008, and our other public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

    Table 1
                             Amicus Therapeutics, Inc.
                           (a development stage company)
                       Consolidated Statements of Operations
   
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
2. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
3. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
4. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
5. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
6. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
7. Amicus Therapeutics Opens Research Facility in San Diego
8. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
9. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
10. Amicus Therapeutics Announces First Quarter 2008 Financial Results
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015   Tocagen Inc. ... interim data from Tocagen,s ongoing investigational studies were ... of the American Association of Neurological Surgeons (AANS)/Congress ... May 1-2, 2015, in Washington, D.C. ... held a meeting with FDA and continues to ...
(Date:5/4/2015)... May 04, 2015 Marianjoy ... patients with arm and hand impairments by acquiring ... its Oakbrook Terrace network site. , Secured through ... is a highly-regarded treatment option for patients with ... Armeo®Spring, Marianjoy becomes one of just four Illinois ...
(Date:5/1/2015)... May 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... announced that it has priced an underwritten registered offering ... price of $9.00 per share, and granted the underwriters ... to an additional 585,000 shares of its common stock. ... million.  The offering is expected to close on May 6, ...
(Date:5/1/2015)... A new report by  visiongain  forecasts the ... in 2019. That revenue forecast and others appear in  ... ,  published in March 2015. ... and qualitative analyses of the antithrombotic drugs market. Visiongain ... London, UK . It produces analyses to ...
Breaking Biology Technology:Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5
... SCOTTSDALE, Ariz., Aug. 22 Regenesis Biomedical, ... Wound Therapy,System, announced today the addition of two ... directors are Peter G. Savas, Chairman and CEO ... principal with,Bederson and Company., (Logo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU008 ...
... VANCOUVER, Aug. 22 /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals (NASDAQ: ... as,custirsen sodium, received Fast Track designation from the ... docetaxel for progressive,metastatic prostate cancer. OGX-011 is currently ... and breast cancer, and is designed to,inhibit the ...
... TSX Exchange Symbol: RVX, CALGARY, Aug. 21 ... announce that it will host a live,teleconference on ... provide a corporate,update of the Company. Following the ... session., The webcast can be accessed at ...
Cached Biology Technology:Regenesis Biomedical Announces Additions to Board of Directors 2FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 2FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 3FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 4Resverlogix Notice of Conference Call & Webcast 2
(Date:4/2/2015)... Md. , April 2, 2015 At ... Salt Lake City , the American College ... of five new directors to its Board.  Members of ... the ACMG and for forming and advancing its policies ... medical genetics profession. "It,s an eventful time ...
(Date:4/2/2015)... April 2, 2015 Fingerprint Cards ... sensor FPC1025 from the distributor World Peace Industrial Group ... Q2 2015 although the major part of the shipments ... be used by smartphone manufacturers in China ... included in the communicated revenue guidance of + 1 000 ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... cancer cells facing potentially lethal antiestrogen therapy recycle to ... cancer cells have receptors for the hormone estrogen, which ... Patients typically get an antiestrogen such as tamoxifen for ... says Dr. Patricia V. Schoenlein, cancer researcher in the ...
... Madison, WI 1 OCTOBER 2008 Not only ... Houston,s George R. Brown Convention Center, beginning this weekend, ... seven scientific societies, but they are bringing focus to ... Meeting under the theme of "Celebrating the International Year ...
... (NorthShore) and Northwestern University have discovered that fiber optic ... blood levels in the colonic lining (mucosa) in humans, ... cancer. The study appears in the October ... of the American Gastroenterological Association (AGA) Institute. ...
Cached Biology News:Breast cancer cells recycle to escape death by hormonal therapy 2Breast cancer cells recycle to escape death by hormonal therapy 3Earth scientists keep an eye on Texas 2Earth scientists keep an eye on Texas 3Earth scientists keep an eye on Texas 4Earth scientists keep an eye on Texas 5Breakthrough optical technology to assess colon cancer risk, accuracy 2Breakthrough optical technology to assess colon cancer risk, accuracy 3
Perm/Wash Buffer 250 Tests...
Mouse monoclonal to OCIL ( Abpromise for all tested applications)....
... Large T antigen initiates replication ... replication in the presence of ... product can be used in ... Replication Kit cat. no. 8050. ...
NuParaffin Kit Application: Flow Cytometry Reactivity: Human...
Biology Products: